Coherus Oncology (CHRS) Assets Average (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Assets Average data on file, last reported at $262.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 36.02% year-over-year to $262.2 million; the trailing twelve-month figure through Mar 2026 stood at $262.2 million (down 36.02% YoY), and the FY2025 full-year result was $353.4 million, down 34.44% from the prior year.
• Assets Average retreated to $262.2 million in Q1 2026, from $387.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $719.2 million in Q2 2024 to a low of $262.2 million in Q1 2026.
• A 5-year average of $512.2 million and a median of $515.9 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 64.95% in 2024 and plunged 43.65% in 2025, its largest moves.
• Tracing CHRS's Assets Average over 5 years: stood at $515.9 million in 2022, then rose by 17.6% to $606.7 million in 2023, then retreated by 21.42% to $476.8 million in 2024, then declined by 18.74% to $387.4 million in 2025, then sank by 32.33% to $262.2 million in 2026.
• Business Quant data shows CHRS's Assets Average at $262.2 million in Q1 2026, $387.4 million in Q4 2025, and $478.0 million in Q3 2025.